Cardiotoxicity induced by anticancer treatment still remains an unanswered problem strongly affecting the quality of life and the overall survival of cancer patients. The most typical form of cardiotoxicity, a dilated cardiomyopathy, usually becomes manifest late in the course of the disease and it is classically considered to be refractory to therapy. Prevention of cardiotoxicity remains the most important strategy and several measures, including cardiac function monitoring, limitation of chemotherapy dose, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers, have been proposed. The response tomodern heart failure therapy of chemotherapy-induced cardiomyopathy has never been evaluated in clinical trials, and evidence-based recommendations for its treatment are still lacking. Although it is likely that angiotensinconverting- enzyme inhibitors and beta-blockers, used for other forms of cardiomyopathy may be highly effective also in this setting, there is still some unjustified concern to use them in asymptomatic cancer patients, and current management mainly focuses on treatment of only symptomatic patients.
- Chemotherapy-induced cardiomyopathy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Radiology Nuclear Medicine and imaging